Sarepta Therapeutics Stock Options
| SRPT Stock | USD 76.33 2.23 3.01% |
Sarepta Therapeutics' latest option contracts expiring on May 16th 2025 are carrying combined implied volatility of 0.9 with a put-to-call open interest ratio of 0.52 over 53 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on May 16th 2025. The total put volume is at 17.0, with calls trading at the volume of 506. This yields a 0.03 put-to-call volume ratio.
Open Interest Against May 16th 2025 Option Contracts
Sarepta Therapeutics option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Sarepta Therapeutics' lending market. For example, when Sarepta Therapeutics' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Sarepta Therapeutics, he or she must hedge the risk by shorting Sarepta Therapeutics stock over its option's life.
2025-05-16
The chart above shows Sarepta Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Sarepta Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Sarepta Therapeutics' option, there is no secondary market available for investors to trade.
Sarepta Therapeutics Maximum Pain Price Across 2025-05-16 Option Contracts
Max pain occurs when Sarepta Therapeutics' market makers reach a net positive position across all Sarepta Therapeutics' options at a strike price where option holders stand to lose the most money. By contrast, Sarepta Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Sarepta Therapeutics
Analyzing Sarepta Therapeutics' in-the-money options over time can help investors to take a profitable long position in Sarepta Therapeutics regardless of its overall volatility. This is especially true when Sarepta Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Sarepta Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Sarepta Therapeutics' stock while costing only a fraction of its price.
Sarepta Therapeutics In The Money Call Balance
When Sarepta Therapeutics' strike price is surpassing the current stock price, the option contract against Sarepta Therapeutics stock is said to be in the money. When it comes to buying Sarepta Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Sarepta Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Sarepta Current Options Market Mood
Sarepta Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Sarepta Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Sarepta Therapeutics' options investors are not very successful. Sarepta Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Sarepta contract
Base on the Rule 16, the options market is currently suggesting that Sarepta Therapeutics will have an average daily up or down price movement of about 0.0563% per day over the life of the 2025-05-16 option contract. With Sarepta Therapeutics trading at USD 76.33, that is roughly USD 0.0429. If you think that the market is fully incorporating Sarepta Therapeutics' daily price movement you should consider buying Sarepta Therapeutics options at the current volatility level of 0.9%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Sarepta |
Purchasing Sarepta Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Sarepta calls. Remember, the seller must deliver Sarepta Therapeutics stock to the call owner when a call is exercised.
Sarepta Therapeutics Option Chain
When Sarepta Therapeutics' strike price is surpassing the current stock price, the option contract against Sarepta Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Sarepta Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Sarepta. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Sarepta. It also shows strike prices and maturity days for a Sarepta Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | SRPT250516C00195000 | 2 | 195.0 | 0.0 - 0.75 | 1.45 | Out |
Call | SRPT250516C00190000 | 6 | 190.0 | 0.0 - 0.75 | 1.6 | Out |
Call | SRPT250516C00185000 | 56 | 185.0 | 0.0 - 0.75 | 0.97 | Out |
Call | SRPT250516C00180000 | 20 | 180.0 | 0.0 - 0.75 | 0.75 | Out |
Call | SRPT250516C00175000 | 34 | 175.0 | 0.0 - 0.5 | 0.1 | Out |
Call | SRPT250516C00170000 | 41 | 170.0 | 0.0 - 0.75 | 0.4 | Out |
Call | SRPT250516C00165000 | 4 | 165.0 | 0.0 - 0.75 | 1.5 | Out |
Call | SRPT250516C00160000 | 21 | 160.0 | 0.0 - 0.75 | 0.8 | Out |
Call | SRPT250516C00155000 | 3 | 155.0 | 0.0 - 0.75 | 3.04 | Out |
Call | SRPT250516C00150000 | 10 | 150.0 | 0.05 - 0.7 | 1.3 | Out |
Call | SRPT250516C00145000 | 38 | 145.0 | 0.0 - 0.75 | 1.2 | Out |
Call | SRPT250516C00140000 | 293 | 140.0 | 0.0 - 0.75 | 0.65 | Out |
Call | SRPT250516C00135000 | 53 | 135.0 | 0.0 - 0.3 | 0.25 | Out |
Call | SRPT250516C00130000 | 33 | 130.0 | 0.05 - 0.75 | 1.3 | Out |
Call | SRPT250516C00125000 | 50 | 125.0 | 0.0 - 0.9 | 0.35 | Out |
Call | SRPT250516C00120000 | 335 | 120.0 | 0.05 - 0.95 | 0.4 | Out |
Call | SRPT250516C00115000 | 8 | 115.0 | 0.05 - 0.95 | 3.1 | Out |
Call | SRPT250516C00110000 | 75 | 110.0 | 0.35 - 0.65 | 0.5 | Out |
Call | SRPT250516C00105000 | 87 | 105.0 | 0.55 - 0.7 | 0.7 | Out |
Call | SRPT250516C00100000 | 630 | 100.0 | 0.85 - 1.1 | 0.88 | Out |
Call | SRPT250516C00095000 | 28 | 95.0 | 1.25 - 1.6 | 1.46 | Out |
Call | SRPT250516C00090000 | 577 | 90.0 | 2.1 - 2.25 | 2.06 | Out |
Call | SRPT250516C00085000 | 159 | 85.0 | 2.85 - 3.2 | 3.2 | Out |
Call | SRPT250516C00080000 | 210 | 80.0 | 4.3 - 4.8 | 4.6 | Out |
Call | SRPT250516C00075000 | 95 | 75.0 | 6.3 - 6.6 | 6.64 | Out |
Call | SRPT250516C00070000 | 32 | 70.0 | 8.9 - 9.3 | 9.43 | In |
Call | SRPT250516C00065000 | 1 | 65.0 | 12.0 - 12.7 | 13.0 | In |
Put | SRPT250516P00195000 | 0 | 195.0 | 118.8 - 122.7 | 118.8 | In |
Put | SRPT250516P00190000 | 0 | 190.0 | 113.8 - 117.7 | 113.8 | In |
Put | SRPT250516P00185000 | 0 | 185.0 | 108.8 - 112.7 | 108.8 | In |
Put | SRPT250516P00180000 | 0 | 180.0 | 103.8 - 107.7 | 46.26 | In |
Put | SRPT250516P00175000 | 0 | 175.0 | 98.9 - 102.7 | 98.9 | In |
Put | SRPT250516P00170000 | 0 | 170.0 | 93.8 - 97.6 | 93.8 | In |
Put | SRPT250516P00165000 | 0 | 165.0 | 88.8 - 92.7 | 88.8 | In |
Put | SRPT250516P00160000 | 0 | 160.0 | 83.8 - 87.7 | 83.8 | In |
Put | SRPT250516P00155000 | 0 | 155.0 | 78.8 - 82.7 | 32.72 | In |
Put | SRPT250516P00150000 | 0 | 150.0 | 73.8 - 77.7 | 31.69 | In |
Put | SRPT250516P00125000 | 10 | 125.0 | 48.8 - 52.7 | 49.05 | In |
Put | SRPT250516P00120000 | 253 | 120.0 | 44.6 - 46.9 | 41.37 | In |
Put | SRPT250516P00115000 | 7 | 115.0 | 38.8 - 42.8 | 19.32 | In |
Put | SRPT250516P00110000 | 14 | 110.0 | 34.1 - 37.7 | 9.13 | In |
Put | SRPT250516P00105000 | 281 | 105.0 | 30.8 - 31.8 | 26.1 | In |
Put | SRPT250516P00100000 | 286 | 100.0 | 26.0 - 26.6 | 22.31 | In |
Put | SRPT250516P00095000 | 35 | 95.0 | 21.2 - 22.1 | 21.05 | In |
Put | SRPT250516P00090000 | 23 | 90.0 | 17.0 - 17.8 | 17.2 | In |
Put | SRPT250516P00085000 | 44 | 85.0 | 12.9 - 13.8 | 12.2 | In |
Put | SRPT250516P00080000 | 22 | 80.0 | 9.5 - 10.1 | 10.1 | In |
Put | SRPT250516P00075000 | 205 | 75.0 | 6.6 - 6.9 | 6.7 | In |
Put | SRPT250516P00070000 | 83 | 70.0 | 4.3 - 4.6 | 4.85 | Out |
Put | SRPT250516P00065000 | 145 | 65.0 | 2.6 - 2.8 | 3.03 | Out |
Put | SRPT250516P00060000 | 36 | 60.0 | 1.4 - 1.95 | 1.58 | Out |
Put | SRPT250516P00055000 | 56 | 55.0 | 0.8 - 1.05 | 0.97 | Out |
Put | SRPT250516P00050000 | 3 | 50.0 | 0.05 - 1.1 | 0.51 | Out |
Sarepta Therapeutics Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
Sarepta Therapeutics Market Cap Over Time
Market Cap |
| Timeline |
Sarepta Total Stockholder Equity
Total Stockholder Equity |
|
Sarepta Therapeutics Corporate Management
| Ryan JD | General VP | Profile | |
| Will Tilton | Head VP | Profile | |
| Joseph Bratica | Controller VP | Profile | |
| William Ciambrone | Ex Operations | Profile | |
| Dallan Murray | Executive Officer | Profile |
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.